The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest of the patient monitoring stocks fared in Q4.
John Bean has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.5%, reaching $125.32 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Over the past six months, Owens Corning’s shares (currently trading at $139.79) have posted a disappointing 12.6% loss, well below the S&P 500’s 1.5% gain. This may have investors wondering how to approach the situation.
Over the last six months, Resideo’s shares have sunk to $17.21, producing a disappointing 5.2% loss - a stark contrast to the S&P 500’s 1.6% gain. This might have investors contemplating their next move.
Since September 2024, AECOM has been in a holding pattern, posting a small return of 0.8% while floating around $96.60.
Meritage Homes’s stock price has taken a beating over the past six months, shedding 22.2% of its value and falling to $74.61 per share. This may have investors wondering how to approach the situation.
Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six months while the S&P 500 has gained 1.6%.
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the online marketplace stocks, including The RealReal (NASDAQ:REAL) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the professional tools and equipment industry, including Fortive (NYSE:FTV) and its peers.